New Hepatitis C Virus Research Reported from Ain Shams University (Angiopoietin-2 as a Predictor of Fibrosis Regression in Hepatitis C Virus-Patients after Direct Acting Antiviral Drugs).

A recent study conducted at Ain Shams University in Egypt explored the role of angiopoietin-2 (Ang-2) in predicting the regression of fibrosis in chronic hepatitis C virus (HCV) patients receiving direct-acting antiviral (DAA) drugs. The researchers found that elevated levels of Ang-2 were correlated with liver stiffness and disease progression from chronic hepatitis to cirrhosis. However, after DAA therapy, there was a significant improvement in fibrosis stage, liver fibrosis indices, and liver and spleen size. The study suggests that Ang-2 can be a useful predictor of fibrosis regression in chronic HCV patients receiving DAA drugs. [Extracted from the article]